Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tredaptive in Stable Coronary Artery Disease
NCT01052311Phase 4Terminated
- Sponsor
- Sheba Medical Center
- Start
- Jul 2010
- Primary completion
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of laropiprant in coronary artery disease (CAD) and dyslipidemia, sponsored by Sheba Medical Center. Primary endpoint: Brachial artery vasoreactivity at 3 months. Started Jul 2010; status: terminated.
02
Drugs
laropiprant
03
Conditions
coronary artery disease (CAD)dyslipidemia
Beyond the preview
Go deeper on NCT01052311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01052311.